

RECEIVED

NOV 2 1999

TECH CENTER 1600/2900

Page 2 response in Ser. No. 03/123,620

Cancel Claims 4 and 8.

Add the following claims.

12. A process for inhibiting NF- κ B in a mammalian cell in which NF- κ B has been activated by an agency external to said cell which comprises administering to the mammal in whose cells NF- κ B has been activated, an NF- κ B inhibiting amount of a free-radical scavenger.

13. A process for inhibiting NF- κ B in a mammalian cell in which NF- κ B has been activated by an agency external to said cell which comprises administering to the mammal in whose cells NF- κ B has been activated, an NF- κ B inhibiting amount of a ribonucleotide reductase inhibitor.

REMARKS

Applicant has amended Claim 1 and written Claims 4 and 8 in independant form as Claims 12 and 13. It is submitted that Claim 1 as amended obviates the Examiner's objection the the claim as stated in the Office Action. Rewriting Claims 4 and 8 in independant form also removes the Examiner's objection that the claims as originally written were duplicates of Claim 1. Applicant realizes that there are now 3 generic claims present, and if the Examiner believes that restriction is necessary, Applicant will elect the species of Claim 1.

The Examiner objects to Claims 9-11 on the ground that all these external agencies are not set forth specifically in the specification. The specification has been amended to specifically refer to "tissue transplants, organ transplants, cell transplants, arteriosclerosis and diabetes" as suggested by the Examiner. Such amendment to the specification does not introduce any new matter since, as pointed out by the Examiner, Claims 9-11 were part of the specification as filed.